secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001447362-23-000065
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences Q1 revenue up 57% to $42M; reaffirms FY 2023 guidance $170-180M
--------------------------------------------------------------------------------

- Delivered 14,916 total test reports (+73% YoY); DecisionDx-Melanoma 7,583 (+26%), DecisionDx-SCC 2,411 (+111%).
- Revenue $42.0M (+57% YoY); adjusted revenue $43.4M (+65%); net loss ($29.2M) vs ($24.6M) prior year.
- Gross margin 70.5% (adjusted 76.5%); cash & marketable securities $232.1M as of March 31, 2023.
- Reaffirms full-year 2023 revenue guidance of $170-180M; Q1 cash use includes $17.7M non-recurring bonus/benefit payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736223000065/0001447362-23-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736223000065/cstl-20230503.htm
  HTML page:      https://secwatch.observer/filing/0001447362-23-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer